These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26185459)

  • 21. Mechanism of action of oritavancin and related glycopeptide antibiotics.
    Allen NE; Nicas TI
    FEMS Microbiol Rev; 2003 Jan; 26(5):511-32. PubMed ID: 12586393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.
    Wu G; Truong J; Lee S; Elnadoury O; Kuan W; Abraham T; Wu A; Liu M
    Expert Rev Anti Infect Ther; 2015 Apr; 13(4):409-16. PubMed ID: 25661747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telavancin: a new lipoglycopeptide for gram-positive infections.
    Smith WJ; Drew RH
    Drugs Today (Barc); 2009 Mar; 45(3):159-73. PubMed ID: 19436839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis.
    Johnson JA; Feeney ER; Kubiak DW; Corey GR
    Open Forum Infect Dis; 2015 Dec; 2(4):ofv156. PubMed ID: 26677455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oritavancin: A Novel Lipoglycopeptide.
    Mattox J; Belliveau P; Durand C
    Consult Pharm; 2016 Feb; 31(2):86-95. PubMed ID: 26842686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dalbavancin: a review for dermatologists.
    Scheinfeld N
    Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD; Pawlak J; Johnson LB
    Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
    Belley A; Lalonde Seguin D; Arhin F; Moeck G
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections.
    Jafari Saraf L; Wilson SE
    Infect Drug Resist; 2011; 4():87-95. PubMed ID: 21694912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.
    Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Zhanel GG
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):311-5. PubMed ID: 25294303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oritavancin for acute bacterial skin and skin structure infections.
    Messina JA; Fowler VG; Corey GR
    Expert Opin Pharmacother; 2015 May; 16(7):1091-8. PubMed ID: 25803197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
    Crandon J; Nicolau DP
    Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of oritavancin for the treatment of acute bacterial skin and skin structure infections.
    García Robles AA; López Briz E; Fraga Fuentes MD; Asensi Diez R; Sierra Sánchez JF
    Farm Hosp; 2018 Mar; 42(2):73-81. PubMed ID: 29501059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycopeptide antibiotics: from conventional molecules to new derivatives.
    Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
    Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
    Mercier RC; Stumpo C; Rybak MJ
    J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011.
    Morrissey I; Seifert H; Canton R; Nordmann P; Stefani S; Macgowan A; Janes R; Knight D;
    J Antimicrob Chemother; 2013 Jan; 68(1):164-7. PubMed ID: 22941898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.